Clinical Study of Tacrolimus Combined with Cyclophosphamide in the Treatment of Patients with Systemic Lupus Erythe-matosus
Objective To explore the clinical effect of tacrolimus combined with cyclophosphamide in the treatment of patients with systemic lupus erythematosus(SLE).Methods 70 patients with SLE admitted to our hospital from January 2021 to September 2022 were selected and randomly divided into two groups,with 35 cases in each group.The control group was treated with cyclophosphamide,and the study group was treated with tacrolimus on the basis of the control group.The clinical efficacy,inflammatory factors and immunoglobulin levels were compared between the two groups.Results The total effective rate of treatment in the study group was 94.29%,significantly higher than 77.14%in the control group(P<0.05).After treatment,the levels of serum IL-6 and TNF-α in the study group were significantly lower than those in the control group(P<0.05).After treatment,the levels of IgA,IgG and IgM in the study group were significantly lower than those in the control group(P<0.05).Conclusions Tacrolimus combined with cyclophosphamide in the treatment of patients with SLE has significant effect,which can obviously reduce the levels of inflammatory factors and inhibit the immune response of the body.
国家科技期刊平台
NSTL
万方数据
